EyePoint Pharmaceuticals, Inc.

Contributing Author

Recent Articles by EyePoint Pharmaceuticals, Inc.

Feb-25	EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 EYPT GlobeNewswire
Feb-24	EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
Feb-18	EyePoint Appoints Michael Campbell as Chief Commercial Officer EYPT GlobeNewswire
Feb-17	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT +15.22% GlobeNewswire
Feb-05	EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 EYPT GlobeNewswire
Jan-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Jan-07	EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 EYPT GlobeNewswire
Dec-17	EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference EYPT GlobeNewswire
Dec-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Nov-19	EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration EYPT GlobeNewswire
Nov-17	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT +13.43% GlobeNewswire
Nov-05	EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments EYPT -11.10% GlobeNewswire
Nov-03	EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
Oct-29	EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 EYPT GlobeNewswire
Oct-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Oct-14	EyePoint Announces Pricing of Public Offering EYPT -10.87% GlobeNewswire
Oct-14	EyePoint Announces Proposed Public Offering of Common Stock EYPT -10.87% EYPT GlobeNewswire
Oct-14	EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema EYPT -10.87% EYPT GlobeNewswire
Sep-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Aug-26	EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
Aug-18	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Aug-06	EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference EYPT GlobeNewswire
Aug-06	EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire
Jul-30	EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 EYPT GlobeNewswire
Jul-29	EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration EYPT GlobeNewswire
Jul-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Jun-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
May-28	EyePoint Announces Participation at Upcoming Investor Conferences EYPT +18.12% GlobeNewswire
May-27	EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration EYPT GlobeNewswire
May-16	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT +7.17% GlobeNewswire
May-13	EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
May-07	EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire

EyePoint Pharmaceuticals, Inc.

Recent Articles by EyePoint Pharmaceuticals, Inc.

Upgrade your FINVIZ experience